Illumina (NASDAQ: ILMN) has raised its fiscal year 2026 guidance for both adjusted earnings per share and total sales, surpassing prevailing analyst estimates. The genetic sequencing and data analysis company announced the upward revision in its latest financial update, reflecting improved operational confidence. This adjustment positions Illumina’s projected metrics above market expectations, indicating a positive trajectory for the remainder of the fiscal period.

The most significant change relates to profitability metrics. Illumina increased its adjusted EPS guidance range from $5.15-$5.30 to $5.30-$5.40. This new upper bound exceeds the analyst consensus estimate of $5.23. The revision suggests that the company anticipates higher efficiency or revenue generation than previously communicated.

Simultaneously, the company upgraded its top-line outlook. Total sales guidance was raised from a range of $4.520 billion-$4.620 billion to $4.600 billion-$4.640 billion. This revised forecast also beats the analyst estimate of $4.566 billion. The increase in the lower bound of the sales range by $80 million indicates a firming of demand across its core segments.

Guidance Revisions vs Estimates

What the Numbers Show

The simultaneous upgrade in both top-line and bottom-line metrics highlights a broad-based improvement in business prospects. By raising the floor of its sales guidance to $4.600 billion, Illumina signals that it expects consistent performance even under conservative scenarios. Furthermore, the adjusted EPS range now starts at $5.30, which is already above the prior ceiling of $5.30 and significantly higher than the $5.23 estimate, suggesting strong margin retention or expansion alongside revenue growth.

Leerink Partners analyst Puneet Souda has maintained an Outperform rating on Illumina and raised the price target to $210 from $175. Separately, Canaccord Genuity analyst Kyle Mikson maintained a Hold rating and increased the price target to $190 from $140. These adjustments signal revised valuation outlooks for the company's shares.

Rating and Price Targets

Leerink Partners retained its positive stance, indicating potential upside based on the updated financial model. Canaccord Genuity kept a neutral view, suggesting a balanced risk-reward profile at the new price level.

Illumina is listed on the NASDAQ under the ticker symbol ILMN.